To study the effects of low-intensity anticoagulation with warfarin in comparison with a placebo for primary stroke prevention in patients with nonrheumatic atrial fibrillation.
- Warfarin (Coumadin®)Drug
Intervention Desc: Anticoagulant (Vitamin K antagonist)
Prospective, randomized, double-blind, placebo-controlled, trial of 571 men at 16 Department of Veterans Affairs medical centers.
Patients were randomized to receive adjusted-dose warfarin with a target prothrombin time ratio of 1.2 -1.5 (estimated INR equivalent of 1.4-2.8) or placebo for the duration of the study.
|Type||Measure||Time Frame||Safety Issue|
|Secondary||Cerebral hemorrhage and death.|